Items Tagged with 'Boston Scientific FDA'

ARTICLES

BSX Reports Net Sales of $1.828 Billion

Boston Scientific Financials Released

On July 26, 2012, Boston Scientific Corporation (NYSE: BSX) released financial results for the second quarter ended on June 30, 2012.


Read More
BSX Acquires Cameron Health for $150 Million

Boston Scientific Acquisition Announced

On June 8, 2012, Boston Scientific Corporation (NYSE: BSX) closed its acquisition of Cameron Health, Inc. of San Clemente, California, and, as a result, added to its product portfolio the world's first and only commercially available subcutaneous implantable cardioverter defibrillator, called the S-ICD® System.


Read More
BSX Receives FDA Approval

Boston Scientific FDA Approval Granted

On June 4, 2012, Boston Scientific Corporation (NYSE: BSX) announced U.S. Food and Drug Administration (FDA) regulatory approval of 32 mm and 38 mm lengths for the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System.


Read More
BSX Recieves FDA Pacemaker Approval

Boston Scientific FDA Approval Granted

On May 7, 2012, Boston Scientific Corporation (NYSE: BSX) announced U.S. Food and Drug Administration (FDA) approval and market launch of its INGENIO and ADVANTIO pacemakers and INVIVE cardiac resynchronization therapy pacemakers (CRT-P).


Read More

Boston Scientific FDA Approval Granted

On February 22, 2012, Boston Scientific Corporation's (NYSE: BSX) ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System and TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent System have received U.S. Food and Drug Administration (FDA) approval for use in patients experiencing an acute myocardial infarction (AMI), or heart attack.


Read More

Boston Scientific FDA Approval Granted

On December 8, 2011, Boston Scientific Corporation (NYSE: BSX) announced U.S. Food and Drug Administration (FDA) approval of the Infinion™ 16 Percutaneous Lead for its Precision Plus™ Spinal Cord Stimulator (SCS) System, the first rechargeable SCS device for chronic pain management.


Read More

Boston Scientific FDA Approval Granted

On November 30, 2011, Boston Scientific Corporation (NYSE: BSX) announced FDA approval of its INCEPTA™, ENERGEN™ and PUNCTUA™ cardiac resynchronization therapy defibrillators and implantable cardioverter defibrillators to treat heart failure and sudden cardiac death. 


Read More

Profit from The Turnaround Letter's...

  • Market-Beating Investment Results
  • 28+ Years of Turnaround Experience
  • Diverse Stock Picks for Today's Unpredictable Market

Distressed Investing Blog

Distressed Investing Blog

Nothing Happened in October, Right?

The S&P 500 is up about 0.6% for the month. That makes the month seem pretty uneventful and benign. But for anyone following the stock market day-by-day, October seemed anything but uneventful and benign. Learn how contrarians can leverage this information for value stock opportunity. Read More.

Free Stock Report

 

Put George Putnam's 28+ years of market-beating, contrarian investing advice to work for you, and give your portfolio a boost with this FREE stock report.

Current Total Returns

 

Value Stock Profit

Total returns cover the fulll year 2013.

Note: Returns are not adjusted for inflation.

 

Read More.

Sample Issue

TL Spotlight

George Putnam has always followed the same straight-forward and highly-profitable investment philosophy. He published his first Turnaround Letter issue back in 1986, and readers have seen extraordinary short and long-term stock profit ever since.

 

In fact, 11 of this year's 12 sales recommendations saw gains--with five of those enjoying total returns greater than 100%. The Turnaround Letter's average profit for 2014's closed out stock picks is +82%:

 

2014 Closed Out Purchase Recommendations

Value Stock Picks

* Calculation includes dividends and price changes between purchase recommendation and current price.

 

Learn more.